Resource library

Videos

14 December 2021

Median Technologies: iBiopsy®, enhancing imaging diagnostic accuracy

Learn more about Median and iBiopsy®, our unique end-to-end AI-powered Software as a Medical Device (SaMD) that supports radiologists and clinicians in the…

See all videos

Brochures

See all brochures

White papers

Understanding Novel Response Patterns of Immunotherapies

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based response assumptions to immunotherapy trials can result in inaccurate interpretation of response, premature therapy termination, and unnecessary removal of subjects from a trial. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.

See all white papers

Case studies

How automation can improve data consistency/value, and streamline study workflow

See all case studies

Scientific publications

The adjudication rates between readers in blinded independent central review (BICR) of advanced esophageal cancer trials with or without immune checkpoint initiators as first line therapy

Yan Liu [1], Yi Wang [1], Antoine Iannessi [1] - Affiliations: [1] Median Technologies, Valbonne, France

Poster presented at the ASCO Annual Meeting – June 4-6, 2022.

The objectives of this work are to document the proportion of reader discrepancies, to evaluate reader performance and to provide suggestions for the reduction of read inconsistency.

See all scientific publications